Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Relief Therapeutics Hldg Ag (OP: RLFTF )

5.665 +0.070 (+1.25%)
Streaming Delayed Price Updated: 10:13 AM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 664
Open 5.530
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 5.595
Today's Range 5.530 - 5.665
52wk Range 1.100 - 7.660
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
Via ACCESSWIRE
Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger
Via ACCESSWIRE

Performance

YTD
+133.13%
+133.13%
1 Month
-24.47%
-24.47%
3 Month
+357.96%
+357.96%
6 Month
+280.20%
+280.20%
1 Year
+158.68%
+158.68%

More News

Read More
Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE
Via ACCESSWIRE
Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents
Via ACCESSWIRE
Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Relief Therapeutics Secures up to $11 Million from Royalty Sales
Via ACCESSWIRE
RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General Meeting
Via ACCESSWIRE
Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment
Via ACCESSWIRE
Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
Via ACCESSWIRE
Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria
Via ACCESSWIRE
Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024
Via ACCESSWIRE
Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024
Via ACCESSWIRE
RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting
Via ACCESSWIRE
Relief Therapeutics Announces Executive Changes
Via ACCESSWIRE
Relief Therapeutics Announces Notice of Annual General Meeting of Shareholders
Via ACCESSWIRE
Relief Therapeutics Announces New Executive Leadership Team Strengthening Capabilities to Guide the Company through Pipeline Development Initiatives
Via ACCESSWIRE
Relief Therapeutics has Published its Annual Report
Via ACCESSWIRE
Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria
From Eton Pharmaceuticals
Via GlobeNewswire
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
Via ACCESSWIRE
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
Via ACCESSWIRE
Relief Therapeutics Announces CEO Transition
Via ACCESSWIRE
Relief Therapeutics Announces that more than 400,000 of its ADRs are Currently Outstanding and that, as a Result, the Company has Achieved an Important NASDAQ Initial Listing Milestone
Via ACCESSWIRE
Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Via ACCESSWIRE
Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE(R) in the U.S. with Pentec Health
Via ACCESSWIRE
Relief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant Laboratory
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.